Preview Newsletter

XARELTO Media Monitoring – Week of 11-06-15

Client Attorney Privileged/Attorney Work Product/At Request of Counsel

Plaintiff Attorney Press Releases

Xarelto Lawsuit Numbers Now Surpass 1,900 Cases
Nov 2, 2015 | Digital Journal
By Marc Goldich

BloodThinnerHelp.com reports that the number of Xarelto lawsuits filed has now surpassed 1,900. This number is expected to continue to rise and to hit 2,000 in the near future. Xarelto, a newer form of blood thinner which entered the market in 2011, has been cited in these lawsuits to cause adverse health events, generally involving near fatal and even fatal uncontrollable bleeding episodes.
Xarelto Lawsuit Mass Tort Litigation Established By Philadelphia Court Of Common Pleas
Nov 3, 2015 | WFMJ-TV
By Marc Goldich

BloodThinnerHelp.com reports on the establishment of a Xarelto mass tort litigation group in Philadelphia, Pennsylvania. The establishment of this group was ordered by the Philadelphia Court of Common Pleas on January 22nd of 2015. The move was due to 75 individual cases which at that point had been filed against Xarelto manufacturers, all commonly alleging that the blood thinner caused serious injuries and even death after many experienced uncontrollable internal bleeding episodes.
Xarelto Lawsuits Surge In Number Since Formation of MDL
Nov 3, 2015 | KCEN-TV
By Marc Goldich

BloodThinnerHelp.com reports on a recent surge in lawsuit filings concerning Xarelto after the formation of multidistrict litigation. The lawsuits, filed against Bayer AG and Johnson & Johnson (parent company of Janssen Pharmaceuticals), have grown tremendously since Xarelto MDL No. 2592 was formed. These federally-filed cases are being overseen in New Orleans, Louisiana by the Honorable Judge Eldon Fallon.
Xarelto Lawsuit Alleges Drug Failed To Prevent Stroke
Nov 4, 2015 | NTV
By Marc Goldich

BloodThinnerHelp.com reports on the first Xarelto lawsuit filed against Bayer and Johnson & Johnson claiming that the drug was unable to prevent a stroke. While hundreds of people have now filed lawsuits claiming the drug caused uncontrollable bleeding episodes, this is the first noted suit to connect the blood thinner with a stroke.
Xarelto Lawsuit Filed Alleging Drug Caused Georgia Man's Death
Nov 4, 2015 | WGFL-TV
By Marc Goldich

BloodThinnerHelp.com reports on a lawsuit filed on behalf of a man from Georgia who passed away due to internal bleeding complications after taking the blood thinner Xarelto. The federal lawsuit was filed in the state of Louisiana.
Ohio Couple files Xarelto Gastrointestinal Bleeding Lawsuit
Nov 4, 2015 | Xarelto Lawsuit
By Flood Law Group, LLP

A couple from Ohio recently joined the growing number of plaintiffs in the consolidated federal Xarelto lawsuits when they filed a suit claiming the wife’s near-fatal gastrointestinal bleed was a side effect of this anticoagulant medication.
Xarelto Lawsuit Update: New Internal Bleeding Lawsuit Consolidated into MDL
Nov 5, 2015 | WHNS-TV
By Marc Goldich

BloodThinnerHelp.com reports today on one of the more notable cases filed in the Xarelto multidistrict litigation. A lawsuit against the manufacturers of Xarelto was originally filed in the Eastern District of New York and later moved to the Xarelto MDL in the Eastern District of Louisiana, by a Texas woman alleging that Xarelto’s manufacturer’s failure to warn and perform adequate safety testing on the drug led to her serious, long term injuries. Many of the other lawsuits filed in the MDL make similar allegations.

Plaintiff Attorney Blog Posts

Delaware Man Files Xarelto Bleeding Lawsuit
Oct 30, 2015 | Top Class Actions
By Joanna Szabo

A Delaware man filed a Xarelto bleeding lawsuit against Janssen Research & Development, alleging that the anticoagulant caused gastrointestinal bleeding that required hospitalization.
Xarelto Lawsuit Claims
Oct 30, 2015 | Bickelbruer Law

There is one of the countrywide law firms is now offering no compulsion and free case evaluation to anyone who has undergone a hazardous Xarelto bleeding event or other health complication. Therefore those people who are interested in following Xarelto lawsuit, the attorneys at this particular law firm can help find out whiter a person can have a legitimate claim for reimbursement. Given that, the FDA received more than 2000 complaints of the side effects of the use of xarelto, complainant’s law firms all across the country have been energetically screening the nationwide survey of its safety and in discoveries published by the institute for safe medicine practices, there have been 151 deaths following the use of this medication. It is a new kind of blood thinner that was manufactured by Bayer and Johnson and Johnson in 2011 and the sale in this medicine reached to $ 1.3 billion by 2013 which was driven by marketing claims that advertised this medication as a better option to warfarin, which was the regular treatment for anticoagulant.
Xarelto: The Prescriptions and Lawsuits Continue to Grow
Oct 30, 2015 | Xarelto Lawyer

Xarelto, unlike perhaps no other drug, has been the subject of more controversy in recent months. Despite the various studies and patient incidents that seem to grow at an alarming rate, it has continued to be named in more and more lawsuits. Because Xarelto has been prescribed mainly for atrial fibrillation as well as for patients recovering from hip and knee replacement surgery, more patients have been exposed to the drug. As a result, the past three months have seen the number of lawsuits expand by almost 35 percent to number more than 1,700 pending personal injury suits.
Xarelto manufacturers defend their product’s safety with a new study
Oct 30, 2015 | Xarelto Lawsuit Information

Xarelto lawsuits just keep on growing every day. More than 700 adverse events including gastrointestinal bleeding, stroke and blood clots have been associated with the use of Xarelto (rivaroxaban), within just just a couple years from its market release in 2008. In the US Xarelto was approved by the Food and Drugs Administration (FDA) in 2011, to prevent blood clots formation and reduce the risk for stroke in patients with non-valvular atrial fibrillation. As per today, about 1,900 Xarelto lawsuits are currently pending in state and federal courts, with plaintiffs and their relatives asking compensations from the manufacturers Janssen Pharmaceuticals and Bayer AG for the serious injuries, and in some case even death cases they suffered because of this medication.
Latest MDL Xarelto Lawsuit Count Reported At 1,700 Cases
Oct 30, 2015 | The Legal Examiner
By Marc Goldich

BloodThinnerHelp.com reports that Xarelto mass tort litigation has significantly grown in recent months, with 400 lawsuits against the blood-thinner drug’s manufacturers filed in August. The cases have been consolidated to form MDL No. 2592, and are being overseen by the Honorable Judge Eldon E. Fallon. Recent reports have noted that as of the 15th of October, 2015, the Xarelto MDL was made up of 1,689 cases in total. This number has significantly skyrocketed since July, and it is expected to continue to grow.
Xarelto Lawsuit Alleges Drug Caused Gastrointestinal Bleed
Nov 2, 2015 | Top Class Actions
By Robert J. Boumis

A new Xarelto lawsuit has joined the mass litigation that claims Xarelto is a dangerous drug. Plaintiff Cheryl B. of Illinois filed the Xarelto lawsuit over allegations that the anticoagulant caused life-threatening injuries.
Xarelto Uncontrollable Bleeding Lawsuits – The Story So Far
Nov 2, 2015 | Xarelto Lawsuit Information
By Claudio Butticè

Xarelto (Rivaroxaban) is a blood thinner drug that was approved by Food and Drugs Administration (FDA) in 2011. Since its approval, Xarelto adverse events caused hundreds of fatal and near-fatal bleeding accidents, seriously injuring several patients in just three and a half years. The other highly-contested Novel Oral Anticoagulant (NOAC) competitor Pradaxa (dabigatran), was already in the eye of the storm because of its serious side effects. However Xarelto side effects vastly surpassed Pradaxa’s ones, with a total number of Xarelto lawsuits passing over the mark of 1,900 cases filed. Roughly 1600 federal Xarelto lawsuits have been consolidated in a Multi Distric Litigation in Louisiana, while another 300 were consolidated in a mass tort action that will be held in a Pennsylvania court.
Xarelto Lawsuits Move Forward, As Federal Litigation issues New Consent Order
Nov 2, 2015 | Bernstein Liebhard LLP
By Sandy Liebhard

The federal multidistrict litigation involving hundreds of Xarelto lawsuits continues to move forward in the U.S. District Court, Eastern District of Louisiana. According to a Consent Order dated October 18th, the Court has clarified the obligations of all parties to preserve voicemails, instant messages sent or received on an instant messaging system, or text messages sent or received on a cellular phone, smartphone, tablet or other mobile device.
Locations Set For Xarelto Lawsuit Trials Alleging The Blood Thinner Causes Uncontrolled Bleeding
Nov 3, 2015 | Southern Med Law

The Xarelto lawsuit attorneys at Southern Med Law have learned that the first two bellwether trials for Xarelto bleeding side-effects complaints will be held in February 2017 at the U.S. District Court, Eastern District of Louisiana in New Orleans. The third bellwether trial will be held in Mississippi in April 2017 and the fourth trial will be held the following month in Texas at district courts to be named at a future date. The Xarelto lawsuits allege that Bayer and Janssen Pharmaceuticals, which makes and markets the blood thinner, failed to warn doctors and their patients about Xarelto’s potential to cause major bleeding events and there is no effective antidote to stop the bleeding.
Xarelto Lawsuit Update: Florida Woman Files Wrongful Death Lawsuit Against Blood Thinner Manufacturers
Nov 4, 2015 | The Legal Herald
By Marc Goldich

A woman from Florida filed a wrongful death lawsuit alleging that Xarelto was the cause of her late husband's internal bleeding injuries and untimely death. The number of lawsuits filed against the manufacturers of the blood thinner Xarelto in the United States are consistently rising. Recently, a new wrongful death lawsuit has been filed in the Xarelto multidistrict litigation. This lawsuit was initially filed in the United States District Court for the Southern District of Florida and since has been moved to the Xarelto multidistrict litigation in the United States District Court of the Eastern District of Louisiana. This particular lawsuit was filed by a widower from Florida alleged that the drug caused her late husband’s severe internal bleeding incident, injuries, and untimely death. This lawsuit is filed under case number 9:14CV80831.
Xarelto Lawsuit Update
Nov 4, 2015 | d'Oliveira & Associates p.c.
By Paul d'Oliveira

Xarelto is a prescription blood thinner that is taken orally and used to prevent or treat medical conditions such as deep vein thrombosis, atrial fibrillation, pulmonary embolism and stroke. Individuals who have taken Xarelto have reported adverse side effects such as bleeding within the intestines, spine, brain and skull. As a result, they have experienced pain and suffering, undergone additional medical treatments and have been harmed. To take action, they have filed Xarelto lawsuits.
Xarelto Side Effects
Nov 4, 2015 | Xarelto Lawyer Help

Xarelto is a prescription medication that works by preventing blood clots from forming, thereby reducing a patient’s risk of having a stroke. Meant for those with atrial fibrillation, deep vein thrombosis, or those who just had hip or knee replacement surgery, Xarelto, active ingredient rivaroxaban, was designed to be a safer alternative to Warfarin. Unfortunately, the opposite appears to be true. If you or a loved one is a victim of Xarelto’s dangerous side effects, you have the right to take legal action – start by calling a defective pharmaceutical attorney near you today.

Full Text of Articles Below

Client Attorney Privileged/Attorney Work Product/At Request of Counsel

Plaintiff Attorney Press Releases

Xarelto Lawsuit Numbers Now Surpass 1,900 Cases

Nov 2, 2015 | Digital Journal

By Marc Goldich

BloodThinnerHelp.com reports that the number of Xarelto lawsuits filed has now surpassed 1,900. This number is expected to continue to rise and to hit 2,000 in the near future. Xarelto, a newer form of blood thinner which entered the market in 2011, has been cited in these lawsuits to cause adverse health events, generally involving near fatal and even fatal uncontrollable bleeding episodes.
The blood thinner is considered extra dangerous due to the fact that it has no known antidote. If patients taking older forms of blood thinners became injured and bled, for example, doctors were able to administer a vitamin K treatment, which worked as an antidote for their blood thinner and counteracted its effects, allowing their blood to clot. Individuals using Xarelto do not have this option, as the drug doesn’t respond to vitamin K.
Many of the lawsuits filed are against manufacturer Janssen Pharmaceuticals, and its parent company, Johnson & Johnson. They are the first to manufacture a blood thinner that has a one pill a day, one-size-fits-all dosage. These factors, originally thought of as revolutionary and convenient, are now being questioned by individuals filing complaints. The drug is generally given to patients with atrial fibrillation, or who are recovering from knee and hip replacement surgeries.
Since the negative allegations regarding the drug have begun to surface, the U.S. Food and Drug Administration has also issued several warnings about Xarelto use despite its initial approval of the drug.
A study published earlier in the year by the British Medical Journal noted that there was a “twofold higher risk of bleeding with rivaroxaban [Xarelto] compared with warfarin.” Additionally, a 2013 study also indicated that patients treated with Xarelto were at a significantly increased risk for fatal gastrointestinal bleeding compared with those who used older versions of blood thinners such as warfarin.
Last year, the Journal of the American Medical Association published a study which also found that treatment with rivaroxaban (Xarelto) was associated with “severe, symptomatic liver injury.” This danger is not noted by manufacturers.
In the midst of these studies, individuals from across the nation are coming forward with their own personal stories and are filing lawsuits against Xarelto manufacturers. The most recent counts show that currently 1,600 Xarelto lawsuits have been filed federally and consolidated to form multidistrict litigation in Louisiana. Additionally, 300 cases are said to be involved in a mass tort action before a Pennsylvania court. These total cases, now numbering 1,900, are said to represent just the beginning of what is to come.
Attorney Marc Goldich is currently working hard to ensure that anyone who has experienced adverse side effects after using Xarelto has the ability to explore their legal options. He offers free consultations, and indicates that these individuals may be entitled to compensation.
For additional information concerning this press release or to ask questions, please contact Marc Goldich, Esq. at 866-435-8902.
http://www.digitaljournal.com/pr/2729011#ixzz3qkaUfTfO

Return to headline | Return to top
Xarelto Lawsuit Mass Tort Litigation Established By Philadelphia Court Of Common Pleas

Nov 3, 2015 | WFMJ-TV

By Marc Goldich

BloodThinnerHelp.com reports on the establishment of aXarelto mass tort litigation group in Philadelphia, Pennsylvania. The establishment of this group was ordered by the Philadelphia Court of Common Pleas on January 22nd of 2015. The move was due to 75 individual cases which at that point had been filed against Xarelto manufacturers, all commonly alleging that the blood thinner caused serious injuries and even death after many experienced uncontrollable internal bleeding episodes.
The administrative judge ordered the 35 individual Xarelto lawsuits to be transferred to the Complex Litigation Center for discovery and pretrial administration. This move was met with opposition by Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals. An opposition motion filed by their attorneys argued that these cases should not be seen in Philadelphia due to the fact that company headquarters are located in New Jersey and New York. Additionally, they argued that the Philadelphia cases should be combined with those consolidated on a federal level in the Louisiana Xarelto MDL. These arguments were rejected by an administrative judge, however, who noted that both defendants had considerable ties to Philadelphia as well.
Xarelto was approved by the United States Food and Drug Administration in 2011, but has since been the topic of much concern and scrutiny. Many allege that the drug is more dangerous than other blood thinners due to the fact that it has no antidote. Traditional blood thinners did. For example, if someone was using a traditional blood thinner and suffered an uncontrollable bleeding episode, physicians were able to administer vitamin K. This would counteract the effects of the blood thinner and allow their blood to clot, stopping the bleed. Xarelto does not respond to vitamin K, and requires life-saving measures such as blood transfusions.
Due to these issues and others, it is anticipated that many additional Xarelto lawsuits will be filed as things move forward. Attorney Marc Goldich is currently working to ensure that anyone who has used Xarelto and subsequently suffered from severe health issues is able to explore their legal rights. These individuals may be entitled to compensation.
To request additional information regarding this topic or to ask questions, please contact Marc Goldich, Esq. by calling 866-425-8902.
http://www.wfmj.com/story/30426480/xarelto-lawsuit-mass-tort-litigation-established-by-philadelphia-court-of-common-pleas

Return to headline | Return to top
Xarelto Lawsuits Surge In Number Since Formation of MDL

Nov 3, 2015 | KCEN-TV

By Marc Goldich

BloodThinnerHelp.com reports on a recent surge in lawsuit filings concerning Xarelto after the formation of multidistrict litigation. The lawsuits, filed against Bayer AG and Johnson & Johnson (parent company of Janssen Pharmaceuticals), have grown tremendously since Xarelto MDL No. 2592 was formed. These federally-filed cases are being overseen in New Orleans, Louisiana by the Honorable Judge Eldon Fallon.
MDL formation is designed to help make the legal process run more smoothly and efficiently, and to eliminate duplicate discovery. The MDL formation process includes standardized procedural forms which aid in streamlining the litigation. Overall, the allegations against Xarelto manufacturers are able to be broken down and evaluated.
In the latest lawsuits, allegations share many similarities and include: the reckless marketing of a new drug which is more dangerous yet has no great advantage over currently available medications and the promotion of Xarelto as a more convenient blood thinner, despite the fact that there is no known antidote to the drug. Across the board, plaintiffs note that had they been properly made aware of the risks associated with Xarelto, they never would have used the drug to begin with, and would have potentially avoided the serious injuries sustained.
Alleged injuries suffered by the plaintiffs include brain hemorrhaging, gastrointestinal bleeding, subdural and epidural hematoma, stroke, heart attack, blood clots, and rectal bleeding. Most recently as well, lawsuits have indicated liver issues caused by Xarelto. Overall, allegations indicate that use of Xarelto can cause episodes of serious and unstoppable internal bleeding. In many cases, this causes hospitalization of the victim, in some cases, it causes death.
It is fully expected that the lawsuit surge will continue, due to the volume of Xarelto prescriptions that have been given across the country as well as the rate of incidents currently reported, and findings by several studies. In total, recent counts state that Xarelto lawsuits now number somewhere around 1,900.
Attorney Marc Goldich is currently working to ensure that anyone who may want to join the litigation is able to do so. He offers free consultations for those who have used Xarelto and suffered severe health issues, and who wish to evaluate their legal rights. These individuals may be entitled to compensation.
For additional information on this topic or to ask questions, please contact Marc Goldich, Esq. at 866-425-8902.
http://www.kcentv.com/story/30425061/xarelto-lawsuits-surge-in-number-since-formation-of-mdl

Return to headline | Return to top
Xarelto Lawsuit Alleges Drug Failed To Prevent Stroke

Nov 4, 2015 | NTV

By Marc Goldich

BloodThinnerHelp.com reports on the first Xarelto lawsuit filed against Bayer and Johnson & Johnson claiming that the drug was unable to prevent a stroke. While hundreds of people have now filed lawsuits claiming the drug caused uncontrollable bleeding episodes, this is the first noted suit to connect the blood thinner with a stroke.
The lawsuit, filed by the daughter of the victim due to his death, states that the Florida resident died from a stroke suddenly, only four days after he had begun using Xarelto to treat his atrial fibrillation.
Atrial fibrillation is an irregular and usually rapid heartbeat which tends to cause poor blood flow throughout the body. It is not typically a life-threatening condition, and it can come and go, but it can lead to blood clot complications. For this reason, many people with this condition use blood thinners as a preventative measure.
In this case, as alleged by the daughter of the deceased, the man suffered a stroke from the drug. The daughter’s lawsuit was filed in Philadelphia, Pennsylvania. Claims within the suit stated that the medication did not work the way it was advertised to and failed to prevent the man from having a stroke associated with his atrial fibrillation.
In 2011, The U.S. Food and Drug Administration approved Xarelto as a revolutionary new type of blood thinner. The drug allowed patients requiring blood thinners more freedom. With traditional blood thinners, patients were required to follow special diets and get regular check-ups and medication adjustments. Xarelto came on the market as a one-size-fits-all pill, which did not require these things. It came with drawbacks as well, however, one of which was considered to be especially dangerous: the new blood thinner had no antidote.
No antidote means that there is no treatment which can reverse the effects of the blood thinner in case someone is injured and begins to bleed. These individuals can easily experience uncontrollable bleeding, as the Xarelto in their systems does not allow their blood to clot. Physicians have to resort to live-saving measures for patients in this situation, such as blood transfusions.
With traditional blood thinners, patients are able to be treated with vitamin K. This reverses the effects of the drug and allows their blood to clot, avoiding continued uncontrollable bleeding. Xarelto does not respond to vitamin K.
Since this lawsuit, there have also been allegations that the drug’s once-a-day, 24-hour dosage does not, in fact, work for a full 24 hours. A 2014 study also showed that Xarelto levels in a patient’s body fluctuate quite significantly throughout the day–more than three times, in fact, than a comparable blood thinner which is taken twice daily.
Currently, Xarelto lawsuit numbers continue to grow. It is estimated that the multidistrict litigation consolidation now contains almost 1,700 federal suits. Additionally, a mass tort has been set up in Philadelphia with another 400 lawsuits. As additional lawsuits are filed, many are able to join the current litigation.
Attorney Marc Goldich is working to assist anyone who has used Xarelto and experienced an adverse effect. These individuals may be entitled to compensation. He provides free, confidential consultation to those who wish to explore their legal rights.
For additional information on Xarelto and the pending litigation, or to ask questions, contact Marc Goldich, Esq. by calling 866-425-8902.
http://www.nebraska.tv/story/30436277/xarelto-lawsuit-alleges-drug-failed-to-prevent-stroke

Return to headline | Return to top
Xarelto Lawsuit Filed Alleging Drug Caused Georgia Man's Death

Nov 4, 2015 | WGFL-TV

By Marc Goldich

BloodThinnerHelp.com reports on a lawsuit filed on behalf of a man from Georgia who passed away due to internal bleeding complications after taking the blood thinner Xarelto. The federal lawsuit was filed in the state of Louisiana.
Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) are facing allegations that their drug causes significant health risks and serious injuries, including death, due to uncontrollable bleeding.
The complaint was filed on March 20th of 2015, by the son of the victim. The son, a Tennessee resident, alleged that his father died due to uncontrollable bleeding that Xarelto had caused. His case was filed in the United States District Court for the Eastern District of Louisiana under number 2:15-cv-00886. Complaint details explain that the father was prescribed Xarelto in order to treat his atrial fibrillation in November of 2012. By March of the next year, the father had passed away due to internal bleeding that was unable to be stopped.
Unlike traditional blood thinners, Xarelto has no antidote, so those who take the drug are unable to counteract its effects and get their blood to clot, even when injured and bleeding. Traditional blood thinners respond to vitamin K treatments. These treatments reverse the effects of the blood thinners and allow the patient’s blood to clot, preventing the loss of too much blood. Xarelto does not respond to vitamin K, and instead requires life-saving measures such as blood transfusions.
In the complaint filed, the son indicates that had he and his father known about these significant risks, they would have chosen a safer alternative. His complaint alleges that Xarelto manufacturers concealed information showing that the blood thinner could cause these life-threatening, irreversible internal bleeding incidences. It states that the company failed to warn consumers and the medical community about these important factors regarding the drug.
Many other lawsuits for Xarelto which contain similar allegations have been filed across the nation. The lawsuits are being overseen by the Honorable Judge Fallon.
Marc Goldich, Esq. is currently working to ensure that anyone who has used Xarelto and subsequently suffered serious medical issues is able to explore their legal rights. He offers free consultations to these individuals, who may be entitled to compensation.
For additional information on this topic, or to ask questions, please contact attorney Marc Goldich by calling 866-425-8902 today.
http://www.mygtn.tv/story/30436299/xarelto-lawsuit-filed-alleging-drug-caused-georgia-mans-death

Return to headline | Return to top
Ohio Couple files Xarelto Gastrointestinal Bleeding Lawsuit

Nov 4, 2015 | Xarelto Lawsuit

By Flood Law Group, LLP

A couple from Ohio recently joined the growing number of plaintiffs in the consolidated federal Xarelto lawsuits when they filed a suit claiming the wife’s near-fatal gastrointestinal bleed was a side effect of this anticoagulant medication.
Molly Ann Harr and her husband, Daniel Harr, Jr. filed their Xarelto lawsuit in the U.S. District Court for the Southern District of Ohio last month. According to their lawsuit, Molly Ann Harr began taking Xarelto in September 2013 to help prevent blood clots which could be caused by her atrial fibrillation. Within two months, she was diagnosed with severe gastrointestinal bleeding and related anemia, which she claims resulted in long-term health issues for her.
Mrs. Harr states in the lawsuit that in 2012, the year before she was prescribed Xarelto, at least 2,081 adverse events and 151 deaths were associated with Xarelto side effects including gastrointestinal bleeding and other forms of internal bleeding. However, Harr says, the potential risk of internal bleeding side effects was still not adequately warned of on Xarelto labels when she began to take the medication the following year.
The Xarelto lawsuit recently filed by Mr. and Mrs. Harr will be centralized in the Eastern District of Louisiana before U.S. District Judge Eldon Fallon in what is called a multidistrict litigation (MDL). When multiple plaintiffs file similar federal lawsuits against the same defendant, they may be consolidated into an MDL to reduce duplicative discovery, prevent conflicting rulings, and to serve the convenience of all parties involved.
In the case of the Xarelto MDL, which currently holds more than 1000 claims, all plaintiffs claim that the makers of Xarelto (rivaroxaban) failed to provide fair and adequate warning of serious and potentially fatal Xarelto side effects including internal bleeding. When Xarelto was first introduced in 2011, it was aggressively marketed as a safer and more convenient alternative to the previous go-to anticoagulant, Coumadin (warfarin). Many patients favored Xarelto over warfarin when they were told that they would not require routine blood monitoring to ensure proper dosing, as warfarin patients do. However, since then, it has come to light that patients taking Xarelto may actually be well-served by routine blood and dosage monitoring. Additionally, now individuals harmed by Xarelto side effects claim that drug makers should have warned that Xarelto may also lead to internal bleeding, a well-known warfarin side effect. However, while Vitamin K may stop internal bleeding in warfarin patients, there is no such antidote for Xarelto internal bleeding.
A number of injured patients and their loved ones, like the Harrs, have opted to file personal injury lawsuits in pursuit of just compensation for medical bills, suffering, and other damages they believe resulted from unwarned-of Xarelto side effects. To learn more about Xarelto lawsuits and whether you may have a valid claim for compensation, please contact us to schedule a free legal consultation.
http://www.xareltolawsuit.com/news/ohio-couple-files-xarelto-gastrointestinal-bleeding-lawsuit/

Return to headline | Return to top
Xarelto Lawsuit Update: New Internal Bleeding Lawsuit Consolidated into MDL

Nov 5, 2015 | WHNS-TV

By Marc Goldich

BloodThinnerHelp.com reports today on one of the more notable cases filed in the Xarelto multidistrict litigation. A lawsuit against the manufacturers of Xarelto was originally filed in the Eastern District of New York and later moved to the Xarelto MDL in the Eastern District of Louisiana, by a Texas woman alleging that Xarelto’s manufacturer’s failure to warn and perform adequate safety testing on the drug led to her serious, long term injuries. Many of the other lawsuits filed in the MDL make similar allegations.
Allegations Made Against Xarelto’s Manufacturers:
In this particular case, the plaintiff began to take Xarelto after it was prescribed by her doctor to treat a heart condition she suffered from called atrial fibrillation and to prevent blood clots that could result from that condition. The plaintiff, age 73 at the time, was taking the blood thinner for five months when she suffered a serious, life threatening internal bleeding event. The internal bleed left her with serious injury. The complaint filed did not specifically state the exact injuries she suffered, but it did specify that the injuries are permanent and will require long term future care. The lawsuit filed alleges that Xarelto was the proximate cause of her internal bleed, that the manufacturers of Xarelto failed to adequately warn patients and doctors about the true dangers of the drug, and that the manufacturers were negligent in releasing the drug onto the market without also releasing a corresponding antidote.
The Dangers of Xarelto
Lawsuits allege that Xarelto is a much more dangerous drug than other blood thinners on the market because it does not come with a corresponding antidote, meaning that there is no drug available to reverse the anticoagulant effects of Xarelto. This is dangerous because if a patient taking Xarelto suffers from an internal bleed, such as the plaintiff in this case, there is no way short of extreme lifesaving measure to stop the bleed and very often these leave the patient with serious injuries. The FDA has issued several warnings regarding the safety of Xarelto, including two black box warnings. The black box warnings are the strictest warnings the FDA can attach to a drug short of recalling it. It means that there is a reasonable risk of hazard associated with the drug. The FDA warnings regarding Xarelto can be found here.
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.foxcarolina.com/story/30449729/xarelto-lawsuit-update-new-internal-bleeding-lawsuit-consolidated-into-mdl#ixzz3qjQlkvph

Return to headline | Return to top

Plaintiff Attorney Blog Posts

Delaware Man Files Xarelto Bleeding Lawsuit

Oct 30, 2015 | Top Class Actions

By Joanna Szabo

A Delaware man filed a Xarelto bleeding lawsuit against Janssen Research & Development, alleging that the anticoagulant caused gastrointestinal bleeding that required hospitalization.
Plaintiff Victor G., in 2012 was prescribed Xarelto with the intention of reducing his risk of stroke and systemic embolism. At the time, based on the information given by the drug manufacturer, the lawsuit says he believed Xarelto was at least as safe and effective as other options, and that the benefit was greater than the risk.
However, the lawsuit says that while taking Xarelto, the plaintiff began coughing up blood. He claims that taking Xarelto caused permanent injuries.
Xarelto Bleeding Side Effects
Xarelto (rivaroxaban), an anticoagulant produced by Bayer Healthcare, was first approved by the U.S. Food and Drug Administration (FDA) in 2011. Janssen markets Xarelto.
The drug was intended to treat patients undergoing hip or knee replacement surgeries, but was later approved to reduce the risk of stroke and systemic embolism. In 2012, the Xarelto label was updated to include an indication for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
This Xarelto bleeding lawsuit and others like it allege that a series of clinical trials well known in the medical community revealed a link between Xarelto and major bleeding events, such as gastrointestinal bleeding. The studies indicated that Xarelto had a higher rate of major bleeding complications than other drugs.
“Major bleeding” indicates that the bleeding involved a critical organ, led to re-operation, or fatalities.
Xarelto bleeding lawsuits claim that Janssen was not only aware of these studies and the bleeding risks of Xarelto, but failed to report these major bleeding complications as significant adverse effects. On top of this, the lawsuits allege that Janssen failed to adequately warn consumers and the medical community about the major bleeding risk associated with Xarelto.
Despite the manufacturer’s alleged knowledge of these risks, the company continued to market Xarelto in a manner the lawsuit describes as negligent and misleading, diminishing the concern for the serious risks of the drug.
The lawsuit alleges negligence, breach of express and implied warranties, fraudulent misrepresentation and concealment, and negligent misrepresentation
.Xarelto Bleeding Lawsuits
Xarelto is facing hundreds of Xarelto bleeding lawsuits. These lawsuits claim the drug makers failed to be transparent in the warnings about bleeding side effects.
Because there is no antidote for Xarelto bleeding, lawsuits also allege that the drug maker should be held accountable for distributing the drug without have a way to reverse potentially life-threatening side effects.
Plaintiffs further allege that drug makers had a responsibility to provide blood level monitoring for users of the drug, especially after recent studies which have suggested blood level monitoring might significantly assist doctors to care for patients who use Xarelto.
If you or someone you know has experienced Xarelto side effects such as Xarelto bleeding, you may be able to join a class action Xarelto bleeding lawsuit.
The Xarelto Bleeding Lawsuit is Case No. 2:15-cv-015940-EEF-MBN, in the U.S. District Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/211916-delaware-man-files-xarelto-bleeding-lawsuit/

Return to headline | Return to top
Xarelto Lawsuit Claims

Oct 30, 2015 | Bickelbruer Law

here is one of the countrywide law firms is now offering no compulsion and free case evaluation to anyone who has undergone a hazardous Xarelto bleeding event or other health complication. Therefore those people who are interested in following Xarelto lawsuit, the attorneys at this particular law firm can help find out whiter a person can have a legitimate claim for reimbursement. Given that, the FDA received more than 2000 complaints of the side effects of the use of xarelto, complainant’s law firms all across the country have been energetically screening the nationwide survey of its safety and in discoveries published by the institute for safe medicine practices, there have been 151 deaths following the use of this medication. It is a new kind of blood thinner that was manufactured by Bayer and Johnson and Johnson in 2011 and the sale in this medicine reached to $ 1.3 billion by 2013 which was driven by marketing claims that advertised this medication as a better option to warfarin, which was the regular treatment for anticoagulant.
This medication is now approved for a number of suggestions that includes prevention of blood clots in the patients with heart beat confusion which is also known as atrial fibrillation and also to treat deep vein thrombosis or blood clot and besides that this medication is also used to minimize the chances that people going through replacement operation will develop blood clot. In some earlier years it was not so popular and now after some few years of being in the market, the indications have increased that implies claims of Xarelto’s advantage over wayfarin may have been overstated. There is no approved antidote to prevent Xarelto internal bleeding which occurs with this medication at times. Wayfaring bleeding can be prevented through the administration of vitamin K. the need for a reversal means mean that internal bleeding has the prospective to be far more hazardous when it happens in xarelto patients.
The unfavorable events linked with the use of xarelto emerged to be on the rise and according to data from FDA, the organization received more than 500 complication caused by xarelto in the first quarter of 2013. People who have been a victim to these complications can contact the xarelto lawyer to know if the victims qualify to get these claims. People need to understand is that contacting a xarelto lawyer does not mean paying loads of immaterial legal fees and additional expenses that is supposed to be connected with filing a court case and there is a particular law firm that functions on the basis of emergency-fee, which allows you to pay to the firm only if a recovery is made on your behalf. With this opportunity available, people who have suffered life threatening occurrences of internal bleeding or any other injury that may allow us to compensate for damages brought upon our self by our unfortunate circumstances. There have been a number of xarelto lawsuits that has been filed on behalf of individuals who have been a victim to incontrollable internal bleeding cause due to the medication.
http://bickelbruer.org/xarelto-lawsuit-claims.html

Return to headline | Return to top
Xarelto: The Prescriptions and Lawsuits Continue to Grow

Oct 30, 2015 | Xarelto Lawyer

Xarelto, unlike perhaps no other drug, has been the subject of more controversy in recent months. Despite the various studies and patient incidents that seem to grow at an alarming rate, it has continued to be named in more and more lawsuits. Because Xarelto has been prescribed mainly for atrial fibrillation as well as for patients recovering from hip and knee replacement surgery, more patients have been exposed to the drug. As a result, the past three months have seen the number of lawsuits expand by almost 35 percent to number more than 1,700 pending personal injury suits.
Discovering More and More
While the number of lawsuits grows by leaps and bounds, lawyers for patients have continued to uncover additional evidence suggesting Xarelto was causing problems with unexpected bleeding episodes long before the manufacturer started reporting any incidents. What has made the situations with this drug so problematic are the continuing allegations that the manufacturers were well aware of the dangers to patients and failed to properly disclose such concerns. And unlike earlier blood thinners that were introduced for patient use, Xarelto has no known antidote to help control any bleeding episodes.
One-Size-Fits-All Drug
As the lawsuits continue, it has become increasingly apparent that Xarelto was viewed by its manufacturers as a one-size-fits-all drug that could be given to virtually any patient that visited a doctor. Billed as a revolutionary new drug that would surpass anything that earlier blood thinners could do for patients, Xarelto was perceived by patients as a drug that could do no wrong. However, since doctors felt no need to have patients be under intense monitoring for bleeding episodes, it has been given out by more doctors for even more conditions over the past several years. In addition to patients with atrial fibrillation or recovering from various surgeries, Xarelto has in recent years been used for patients experiencing blood clots or similar disorders. However, no matter what condition a patient has had, the results have been the same.
The Future of Blood Thinners
One of the biggest concerns of both patients and doctors based on pending lawsuits is the future of blood thinners. Due to the extremely negative publicity generated by Xarelto, various drug manufacturers are now scrambling to develop safer versions as quickly as possible. Yet despite the attempts to speed up the process, most experts estimate it will be at least another decade before new drugs that are considered safe for patients will be available. However, as the negative publicity continues and the number of lawsuits continues to grow, some health care professionals wonder if the blood thinner class of drugs will ever be able to recover and regain the trust of patients.
http://xareltolawyer.com/articles/xarelto-the-prescriptions-and-lawsuits-continue-to-grow/

Return to headline | Return to top
Xarelto manufacturers defend their product’s safety with a new study

Oct 30, 2015 | Xarelto Lawsuit Information

Xarelto lawsuits just keep on growing every day. More than 700 adverse events including gastrointestinal bleeding, stroke and blood clots have been associated with the use of Xarelto (rivaroxaban), within just just a couple years from its market release in 2008. In the US Xarelto was approved by the Food and Drugs Administration (FDA) in 2011, to prevent blood clots formation and reduce the risk for stroke in patients with non-valvular atrial fibrillation. As per today, about 1,900Xarelto lawsuits are currently pending in state and federal courts, with plaintiffs and their relatives asking compensations from the manufacturers Janssen Pharmaceuticals and Bayer AG for the serious injuries, and in some case even death cases they suffered because of this medication.Is Xarelto a safe medication?
The pharmaceutical companies that produce Xarelto however, are claiming that their product is safe, showing the results of a recent study as proof of their claims. In the latest press release issued by Johnson & Johnson (parent company of Janssen Pharmaceuticals), the company explains that bleeding rates associated with Xarelto are much lower than expected. Both the PMSS (Post-Marketing Safety Surveillance) and XANTUS (Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation) studies, showed positive results regarding Xarelto’s safety: “rates and patterns of major bleeding in routine clinical practice were low (2.89 and 2.1 per 100 person years, respectively), and generally consistent with those observed in Phase 3 clinical research”.
The PMSS study was performed in “real-world settings”, and included more than 45,000 U.S. patients who were evaluated during a period of five year. In this study, the most common Xarelto side effects were gastrointestinal and intracranial bleedings, and the results confirmed the findings of their previous, highly contested study, the ROCKET AF.
The XANTUS observational study reviewed data from roughly 6,800 patients under Xarelto medication for stroke prevention in Europe, Canada, and Israel. The results of this study showed that “the incidence of major bleeding was 2.1 per 100 person-years. Fatal bleeding, critical organ bleeding and intracranial hemorrhage were uncommon, and observed in 0.2, 0.7 and 0.4 per 100 person-years, respectively. The incidence of stroke was 0.7 per 100 person-years.”Is Xarelto a dangerous medication?
Although it’s clear that Janssen Pharmaceuticals and Bayer AG are pushing forward the results of these studies as the final proof required to consolidate the safety of their product, other conflicting results still suggest that Xarelto dangerous side effects should not be underestimated.
Several studies suggested that the risk for bleeding associated with Xarelto could be much higher than its counterpart, the older drug Warfarin. In a 2015 study for example, researchers wrote in its conclusion that the risk of bleeding associated with Xarelto can be as up as twofold higher compared to warfarin. The most alarming consequence of Xarelto bleedings though, is the fact that they cannot be stopped as there’s no antidote available. Unlike warfarin, heparins or clopidogrel (the other most commonly used blood thinners available on the market), there’s no way to reverse Xarelto effects, posing a serious threat to a patient’s life in the occurrence of a bleeding event. Similarly to Xarelto, even the other Novel Oral Anticoagulants (NOACs) Eliquis (apixaban) and Pradaxa (dabigatran), showed an increased risk of bleeding while lacking an effective antidote to reverse their effects. Other studies also suggested a strict association between Xarelto and liver injuries, suggesting that this medication can cause liver damage.
Plaintiffs accused Xarelto manufacturers of negligence in warning patients and doctors about is serious, life-threatening side effects. Although these newer studies seem to show that Xarelto could be safer than it was thought to be, lawsuits keeps being filed in courts across the country. To answer to the large number of accusation against the pharmaceutical companies, in December 2014, the U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated over 1,600 federally filed lawsuits into the Eastern District of Louisiana, with another over 300 proceeding in a mass tort in Pennsylvania.
https://www.xareltocares.com/xarelto/xarelto-manufacturers-defend-their-products-safety-with-a-new-study/

Return to headline | Return to top
Latest MDL Xarelto Lawsuit Count Reported At 1,700 Cases

Oct 30, 2015 | The Legal Examiner

By Marc Goldich

BloodThinnerHelp.com reports that Xarelto mass tort litigation has significantly grown in recent months, with 400 lawsuits against the blood-thinner drug’s manufacturers filed in August. The cases have been consolidated to form MDL No. 2592, and are being overseen by the Honorable Judge Eldon E. Fallon. Recent reports have noted that as of the 15th of October, 2015, the Xarelto MDL was made up of 1,689 cases in total. This number has significantly skyrocketed since July, and it is expected to continue to grow.Current Status of Xarelto Lawsuits in MDL
Currently, pretrial discovery and selection of bellwether trials are taking place for these cases. All contain similar allegations stating that Bayer AG and Johnson & Johnson neglected to properly warn consumers about the dangers of uncontrollable bleeding associated with their drug.
Studies also highlight a potential connection between Xarelto use and an increased risk of an adverse event for those using the drug to treat atrial fibrillation. Those taking older blood thinners who became injured and suffered bleeding episodes were able to be given vitamin K by their physicians, which would counteract the medication and allow the blood to clot. Xarelto, however, does not respond to vitamin K, and, in fact, has no known antidote.Xarelto: A Background To Approval
Xarelto gained approval from the U.S. Food and Drug Administration and first came on the scene seeming like a revolutionary, blockbuster drug. It’s one-size-fits-all formula made it incredibly convenient compared to older blood thinners, which required specific diets and frequent visits to the doctor for monitoring and adjustments. Since new lawsuits have come to life, alleging that Xarelto causes increased risk for uncontrollable bleeding, many physicians have noted that it, too, should be monitored.
It has been noted that, as patients are increasingly prescribed Xarelto for atrial fibrillation or after hip and knee replacement surgeries, the adverse events linked to the drug grow in number as well.
It is currently expected that the first bellwether trials concerning the Xarelto litigation will be seen in court near the beginning of 2017. This timeline leaves plenty of room for others who have used Xarelto and experienced adverse events to also file assuming that the statute of limitations has not run on the claim.QUESTIONS ABOUT THIS RELEASE?
Marc Goldich, Esq. is currently working to assist anyone who would like a free consultation to consider filing a Xarelto lawsuit. These individuals may be entitled to compensation. For additional information on this topic or to ask questions, please contact Attorney Marc Goldich by calling 866-425-8902.
http://philadelphia.legalexaminer.com/xarelto-lawsuits/latest-mdl-xarelto-lawsuit-count-reported-at-1700-cases/

Return to headline | Return to top
Xarelto Lawsuit Alleges Drug Caused Gastrointestinal Bleed

Nov 2, 2015 | Top Class Actions

By Robert J. Boumis

A new Xarelto lawsuit has joined the mass litigation that claims Xarelto is a dangerous drug.
Plaintiff Cheryl B. of Illinois filed the Xarelto lawsuit over allegations that the anticoagulant caused life-threatening injuries.
According to the Xarelto lawsuit, Cheryl’s physicians prescribed her Xarelto in 2013 to control blood clots in her body. However, less than two months after Cheryl took the drug, she was rushed in for emergency medical care.
The Xarelto lawsuit alleges that Cheryl suffered gastrointestinal bleeding from Xarelto. In a gastrointestinal bleed, a minor injury somewhere along the digestive tract, bleeds severely.
Normally, minor injuries to the GI tract may heal themselves. But for a patient on a drug like Xarelto, even minor bleeding events can turn life-threatening due to the way blood thinners like Xarelto work.
Xarelto Bleeding Complications
Xarelto is an anticoagulant or “blood thinner,” a drug designed to interfere with the clotting process. In a healthy person, clotting is a normal part of the healing process after injuries.
But sometimes the process can misfire causing blood clots to form within the body, where they can block critical blood vessels like those of the brain and heart. Medications like Xarelto can help reduce the risk of these dangerous blood clots—but carry risks of their own.
All anticoagulants carry the risk of working too well by blocking the clotting process entirely. When this happens, the tiniest cut or bruise can become a medical emergency.
Since the body cannot stop bleeding, and blood is physically thinner, the patient may bleed to death from very minor injuries. But Xarelto lawsuits allege that Xarelto has special risks above and beyond those of other anticoagulants.
Xarelto Internal Bleeding Lawsuits
Numerous Xarelto lawsuits allege that the blood thinner is not as safe as older anticoagulants. Specifically, anticoagulants that have reversal agents available—a second drug that can shut off the anticoagulant if a patient experiences uncontrollable bleeding.
For example, with Warfarin (Coumadin) a very large dose of vitamin K can actually turn the drug off, and allow patients to form blood clots in an emergency.
This works because Warfarin interferes with the clotting process that depends on vitamin K, and a very large dose of the vitamin can overwhelm Warfarin, effectively turning off the drug.
Despite the fact that Xarelto has no known reversal agent, Xarelto lawsuits allege that the drug’s maker marketed it as safer than traditional medications like Warfarin.
Cheryl’s Xarelto lawsuit describes her gastrointestinal bleeding experience as painful and life threatening. Her lawsuit further alleges that the incident has shortened her life expectancy.
As a result, the Xarelto lawsuit seeks to recoup the costs of medical care, lost wages, compensation for pain and suffering, and other compensation for her alleged Xarelto bleeding.
The Xarelto lawsuit has been filed against several drug companies involved with the production, development, and marketing of Xarelto, including Johnson & Johnson, Bayer, and Janssen Pharmaceuticals.
The Xarelto Internal Bleeding Lawsuit is In RE: Xarelto (Rivaroxaban) Products Liability Litigation, Case No. 2:15-cv-01122-EEF-MBN and MDL No. 2592, in the U.S. District Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/209513-xarelto-lawsuit-alleges-drug-caused-gi-bleed/

Return to headline | Return to top
Xarelto Uncontrollable Bleeding Lawsuits – The Story So Far

Nov 2, 2015 | Xarelto Lawsuit Information

By Claudio Butticè

Xarelto (Rivaroxaban) is a blood thinner drug that was approved by Food and Drugs Administration (FDA) in 2011. Since its approval, Xarelto adverse events caused hundreds of fatal and near-fatal bleeding accidents, seriously injuring several patients in just three and a half years. The other highly-contested Novel Oral Anticoagulant (NOAC) competitor Pradaxa (dabigatran), was already in the eye of the storm because of its serious side effects. However Xarelto side effects vastly surpassed Pradaxa’s ones, with a total number of Xarelto lawsuits passing over the mark of 1,900 cases filed. Roughly 1600 federal Xarelto lawsuits have been consolidated in a Multi Distric Litigation in Louisiana, while another 300 were consolidated in a mass tort action that will be held in a Pennsylvania court.
Plaintiffs accuse Xarelto manufacturers Bayer and Janssen of negligence in providing adequate warnings to physicians and patients about Xarelto life-threatening side effects. They accuse the pharmaceutical companies of hiding critical information about the potential dangers of Xarelto. One of the main issues is the fact that there’s no antidote available to reverse Xarelto bleeding events, posing a serious threat to a patient in case of even a simple domestic accident. Xarelto further lost profit margins as its competitor medication Pradaxa recently received FDA approval for a new reversal agent. According to FiercePharma, the market for blood thinners is one of the fastest growing ones among all types of medications. Reports indicate that potential sales for anticoagulants could top $15 billion by 2018, with Xarelto expected to grab a significant share of the market with at least 20% of total sales.
Xarelto gains FDA’s controverse approval
When Xarelto’s approval was first taken in consideration in 2011, the FDA expressed significant concerns about the ROCKET-AF study that allegedly demonstrated the medication’s purported safety and superiority over its competitor Warfarin (Coumadin). FDA recommendation was against Xarelto’s approval because of “a lack of substantial evidence that rivaroxaban will have its desired effect when used as recommended in labeling” [1]. When the effectiveness of Xarelto in preventing stroke and embolism was compared to warfarin, according to FDA, patients tested spent less than 60% of the time at the optimal international normalized ratio (a value that measures the time required for blood to form a clot: it’s a parameter that defines the effectiveness of oral blood thinners). This value was inferior than it was supposed to be to define Xarelto as safe and effective.
Nonetheless, on July 1, 2011, Xarelto received FDA’s approval for the treatment of patients at risk of deep vein thrombosis and in patients undergoing knee or hip replacement surgery. In the next two years, Xarelto gained FDA’s approval for several other indications, such as the prevention of stroke in patients with atrial fibrillation (AFIB) and the reduction of stroke risk in patients suffering from acute coronary syndrome.
Xarelto side effects and bleeding events
Several studies published in the next few years though, including a recent study published in 2015 in the British Medical Journal, pointed out how Xarelto was far from being a safe medication [2, 3]. Patients treated with Xarelto and other NOACs such as Pradaxa or Eliquis (apixaban), showed a much higher risks of fatal gastrointestinal bleeding and other life-threatening bleeding events compared to those treated with warfarin, up to a “twofold higher risk of bleeding”. Xarelto is also associated with a serious risk for liver injury and damage, posing further concerns about its purported safety [4].
In 2014, the FDA required the makers of Xarelto to add a new warning to the medication’s label, including the infamous “black box” warning. The black box is the FDA’s strongest and most urgent type of warning that informs patients about the potentially fatal side effects of medications [5].
The latest news though is a last-minute announcement about Xarelto’s safety from its own manufacturers. In a recent press release from Xarelto manufacturer company Johnson & Johnson, parent company of Janssen Pharmaceutica, two new studies were published allegedly demonstrating the medication’s safety. The two studies were performed in “real-world settings”, as explained by the pharmaceutical company representatives, to demonstrate that “the use of rivaroxaban in day-to-day care is consistent with the safety profile observed in ROCKET AF, the landmark Phase 3 study used by regulatory authorities worldwide to approve the medicine for the prevention of stroke in patients with non-valvular atrial fibrillation”. The two studies are a Post-Market Safety Surveillance (PMSS) study, and a prospective, observational study called “XARELTO® for Prevention of Stroke in Patients with Atrial Fibrillation” (XANTUS). Both the two studies lacked any comparator arm to determine whether Xarelto is actually a better, safer or more effective medication than its older counterparts though. It should also be noted that both the two studies were designed and funded by Bayer, Janssen Pharmaceutica’s partner in the marketing and sale of Xarelto.
https://www.xareltocares.com/xarelto/xarelto-uncontrollable-bleeding-lawsuits-the-story-so-far/

Return to headline | Return to top
Xarelto Lawsuits Move Forward, As Federal Litigation issues New Consent Order

Nov 2, 2015 | Bernstein Liebhard LLP

By Sandy Liebhard

The federal multidistrict litigation involving hundreds of Xarelto lawsuits continues to move forward in the U.S. District Court, Eastern District of Louisiana. According to a Consent Order dated October 18th, the Court has clarified the obligations of all parties to preserve voicemails, instant messages sent or received on an instant messaging system, or text messages sent or received on a cellular phone, smartphone, tablet or other mobile device.
The provisions of the Order became effective on September 15, 2015. Among other things, Xarelto lawyers were instructed to contact and instruct individual plaintiffs to refrain from initiating text messages, instant messages or voicemail for substantive communications relating to the drug, their medication condition, or claim for damages. Any Plaintiff who does initiate a substantive communication by one of these means is obligated to preserve or transcribe the communication.
The Order contains similar provisions that apply to any of the Defendants’ current U.S. employees who have been designated as document custodians either in Defendants’ Voluntary Disclosures, or via a Plaintiffs’ request.
Xarelto Bleeding Allegations
Court documents indicate that nearly 1,700 product liability claims have been filed in the Eastern District of Louisiana on behalf of individuals who allegedly suffered dangerous episodes of Xarelto bleeding and/or related complications. Plaintiffs accuse the drug’s manufacturers of failing to provide patients with adequate warnings about the serious internal bleeding that can sometimes accompany use of Xarelto, and point out that there is currently no approved antidote to reverse the drug’s anticoagulant effects. The lawsuits also accuse the drug makers of wrongly marketing Xarelto as a superior alternative to warfarin, a blood thinner that has been in use for decades. Among other things, plaintiffs point out that bleeding associated with warfarin can be reversed via the administration of vitamin k.
The Xarelto complaints pending in Louisiana have been centralized so that the federal docket may undergo coordinated pretrial proceedings. The litigation is preparing for its first bellwether trials, which will get underway in 2017.
Bernstein Liebhard LLP represents plaintiffs in Xarelto lawsuits. If you or a loved one were seriously harmed by this blood thinner, please call (888) 979-1182 to arrange for a free legal review with one of our Firm’s attorneys.
http://www.thexareltolawsuit.com/xarelto-lawsuits-move-forward-as-federal-litigation-issues-new-consent-order/

Return to headline | Return to top
Locations Set For Xarelto Lawsuit Trials Alleging The Blood Thinner Causes Uncontrolled Bleeding

Nov 3, 2015 | Southern Med Law

The Xarelto lawsuit attorneys at Southern Med Law have learned that the first two bellwether trials for Xarelto bleeding side-effects complaints will be held in February 2017 at the U.S. District Court, Eastern District of Louisiana in New Orleans. The third bellwether trial will be held in Mississippi in April 2017 and the fourth trial will be held the following month in Texas at district courts to be named at a future date. The Xarelto lawsuits allege that Bayer and Janssen Pharmaceuticals, which makes and markets the blood thinner, failed to warn doctors and their patients about Xarelto’s potential to cause major bleeding events and there is no effective antidote to stop the bleeding.
U.S. District Judge Eldon Fallon, who is presiding over the Xarelto multidistrict litigation, recently released a Case Management Order (CMO) indicating that 40 Xarelto lawsuits will be selected as potential cases for bellwether trials. In the CMO, Judge Fallon directed attorneys for the plaintiffs and the defendants to each choose 10 potential cases for the bellwether pool and he will randomly select 20 cases. The parties will propose specific cases for trial by August 1, 2016. (In Re: Xarelto Products Liability Litigation, MDL No. 2592)
The Xarelto attorneys at Southern Med Law are evaluating Xarelto bleeding lawsuit claims and are offering free legal consultations to those who have suffered dangerous, uncontrolled bleeding allegedly, or those whose loved ones have died allegedly due to the use of the blood thinner Xarelto. Call 1-205-547-5525 or fill out our online form located on the www.southernmedlaw.com website.
Xarelto Complications: Xarelto is a oral blood thinner that received approval by the U.S. Food and Drug Administration (FDA) to reduce the risk of blood clots, pulmonary embolism, deep vein thrombosis, and to prevent stroke in patients with atrial fibrillation not caused by a heart valve problem. Xarelto is manufactured by Bayer Healthcare and marketed in the United States by Janssen Pharmaceuticals Inc. According to the FDA, the most common adverse reactions with Xarelto are bleeding complications yet Xarelto does not have a reversal agent to stop major bleeding. Warfarin, the oldest FDA-approved blood thinner on the market today, uses vitamin K as an antidote to stop bleeding events.
[fda.gov/Drugs/NewsEvents/ucm405148.htm, July 17, 2014]
According to Xarelto bleeding lawsuits, the blood thinner medication quickly became popular due to aggressive marketing of the drug and garnered $582 million in global sales in its first year. Xarelto soon reached blockbuster status after clearing $1 billion in sales and ultimately reaching $2 billion in 2013, according to the Xarelto complaints. The Xarelto lawsuits also state that the World Preview reported that Xarelto is estimated to be the “19th best-selling drug in the world by 2018,” with sales expected to jump from $596 million in 2012 to $3.7 billion in 2018. The Xarelto complaints contend that despite the predictions of enormous sales, the blockbuster drug continues to place patients at risk of severe bleeds and death. (In Re: Xarelto Products Liability Litigation, MDL No. 2592)
Xarelto Bleeding Lawsuit Claims: Court documents indicate that the Xarelto lawsuits continue to be filed in the multidistrict litigation (MDL) pending in the Eastern District of Louisiana. One lawsuit recently filed against Bayer and Janssen Pharmaceuticals involves a Maine woman who was prescribed Xarelto in June 2013. The complaint said the woman was admitted to the hospital about one year later for severe gastrointestinal bleeding and anemia which was allegedly caused by Xarelto. (Case No. 2:15-cv-01760) The Xarelto complaints in the MDL purport that Bayer and Janssen failed to warn about Xarelto’s potential for bleeding complications and there is no effective antidote to reverse the blood thinner’s effects.
About Southern Med Law And Filing Xarelto Bleeding Lawsuit Claim: Throughout his career, Dr. François Blaudeau, a founder of Southern Med Law, has worked hard to develop a strong reputation in healthcare litigation. His first-hand knowledge of medicine has made Southern Med Law an aggressive and effective advocate for those who were harmed due to dangerous and defective drugs and medical devices. If you or a loved one experienced life-threatening Xarelto bleeding complications, please contact the Firm today to learn more about your legal rights. You can arrange for a free, no obligation Xarelto lawsuit review by filling out our online form, or by calling the office directly at 205-547-5525.
https://www.southernmedlaw.com/blog

Return to headline | Return to top
Xarelto Lawsuit Update: Florida Woman Files Wrongful Death Lawsuit Against Blood Thinner Manufacturers

Nov 4, 2015 | The Legal Herald

By Marc Goldich

Florida Woman Files Wrongful Death Lawsuit Against Xarelto Manufacturers
A woman from Florida filed a wrongful death lawsuit alleging that Xarelto was the cause of her late husband's internal bleeding injuries and untimely death. The number of lawsuits filed against the manufacturers of the blood thinner Xarelto in the United States are consistently rising. Recently, a new wrongful death lawsuit has been filed in the Xarelto multidistrict litigation. This lawsuit was initially filed in the United States District Court for the Southern District of Florida and since has been moved to the Xarelto multidistrict litigation in the United States District Court of the Eastern District of Louisiana. This particular lawsuit was filed by a widower from Florida alleged that the drug caused her late husband’s severe internal bleeding incident, injuries, and untimely death. This lawsuit is filed under case number 9:14CV80831.
Xarelto Wrongful Death Lawsuit
The complaint filed in the Xarelto MDL details the events that the plaintiff and her late husband experienced. The plaintiff’s husband was prescribed Xarelto on January 10, 2012 by his primary care physician to treat his atrial fibrillation, a heart condition that put him at risk for blood clots and deep vein thrombosis. After taking the blood thinner for several months, the deceased suffered from a dangerous subdural hemorrhage. Due to the hemorrhage, he was hospitalized for several days where physicians performed extreme, life saving measures to try to stop the bleeding. Unfortunately, due to complications resulting from the internal bleed, the plaintiff’s husband died on June 28, 2012.
The Allegations of a Wrongful Death Lawsuit
This complaint makes several allegations against the manufacturers of Xarelto. They allege that the plaintiff’s husband’s subdural hemorrhage and death can be largely attributed to Xarelto. They also state that the plaintiff’s husband would not have taken Xarelto if he was made aware of the real risks associated with the drug and that he would have instead opted for one of the safer alternatives on the market at the time. The lawsuit also alleges that the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals, were aware of the true dangers of the drug and failed to adequately warn doctors and patients of them. Finally, the compliant states that the manufacturers of Xarelto were reckless in releasing Xarelto onto the market while knowing its true dangers and without also releasing a corresponding antidote to the drug. In this wrongful death lawsuit, the plaintiff is suing for several damages. A wrongful death lawsuit, in general, gives the estate of the deceased the opportunity to recover financial compensation for the harm the deceased suffered. In this particular lawsuit, the family of the deceased is suing for medical, funeral and burial expenses, loss of future income, loss of support, and loss of companionship. For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://legalherald.com/xarelto-lawsuit-update-florida-woman-files-wrongful-death-lawsuit-against-blood-thinner-manufacturers/

Return to headline | Return to top
Xarelto Lawsuit Update

Nov 4, 2015 | d'Oliveira & Associates p.c.

By Paul d'Oliveira

Xarelto is a prescription blood thinner that is taken orally and used to prevent or treat medical conditions such as deep vein thrombosis, atrial fibrillation, pulmonary embolism and stroke. Individuals who have taken Xarelto have reported adverse side effects such as bleeding within the intestines, spine, brain and skull. As a result, they have experienced pain and suffering, undergone additional medical treatments and have been harmed. To take action, they have filed Xarelto lawsuits.
What Is Currently Happening With Xarelto Lawsuits?
As of October 2015, there are 1,698 Xarelto lawsuits pending in the U.S. Court system and more might be filed. Since December 2014, these cases have been consolidated to be heard by one court. The purpose of this is to make the management of the lawsuit more efficient due to the high volume of cases. By doing this, the court system consolidates information and avoids conflicting decisions by multiple judges.What Is Going To Happen Next?
Xarelto lawsuits are progressing and the court will soon begin hearing a sample of cases in what is known as “bellwether” trials. These types of trials are often used during early stages when there are a large number of cases in order to test the claims, evidence and testimony. The outcome of these trials will not be binding on all Xarelto cases but the process gives an idea to both parties on how strong their case is and promotes settlement negotiations.
Below is an estimated timeline for the first scheduled trials. These dates are subject to change based on the discretion of the court.
January 11, 2016 – Case selection begins. Out of the thousands of cases, a sample of 40 cases will be selected. The plaintiff will choose 10 cases, the defendant will choose 10 cases and the remaining 20 cases will be selected randomly.
August 1, 2016 – Case selection ends. By this time, the 40 cases to be heard should be determined.
February 6, 2017 – First trial scheduled
March 13, 2017 – Second trial scheduled
April, 24, 2017 – Third trial scheduled
May 30, 2017 – Fourth trial scheduled
What If I Was Harmed By Taking Xarelto?
Even though Xarelto lawsuits are developing in the court system, it is not too late to take action. If you or someone you know was harmed by taking Xarelto, you may be entitled to compensation for your medical bills, lost income and pain and suffering, among other losses. We are working with experienced Xarelto lawyers who can evaluate your case, file a lawsuit on your behalf and do not charge a fee unless you win a settlement or award. Call us toll free or fill out a contact form online for a free (no obligation) case evaluation.
http://www.good-legal-advice.com/personal-injury-blog/xarelto-lawsuit-update/

Return to headline | Return to top
Xarelto Side Effects

Nov 4, 2015 | Xarelto Lawyer Help

Xarelto is a prescription medication that works by preventing blood clots from forming, thereby reducing a patient’s risk of having a stroke. Meant for those with atrial fibrillation, deep vein thrombosis, or those who just had hip or knee replacement surgery, Xarelto, active ingredient rivaroxaban, was designed to be a safer alternative to Warfarin. Unfortunately, the opposite appears to be true. If you or a loved one is a victim of Xarelto’s dangerous side effects, you have the right to take legal action – start by calling a defective pharmaceutical attorney near you today.
Risks of Xarelto
The risks of Xarelto may be dangerous. A medication guide published by the U.S. Food & Drug Administration lists the potential Xarelto complications as:Bleeding, which can be serious and result in death.Spinal or epidural hematoma (blood clots) that can cause long-term impairment or paralysis.
And unlike Warfarin, which can also cause severe and excessive bleeding, there is no antidote for Xarelto. As such, if severe bleeding occurs, putting
a stop to the bleeding can be extremely difficult, if not impossible.
In a study published in 2015 in Clinical Cardiology, 496 major bleeding events occurred in 478 patients (some patients had more than one major bleeding event), out of a total of 27,467 patients receiving rivaroxaban. The majority of bleeding that occurred was gastrointestinal or intracranial. Of these patients, 14 died during their major bleeding hospitalization.
There Is Help Available
A prescription drug should never be more risky than beneficial for a patient. When a drug causes undue harm due to design or manufacturing defect, or the failure to publish known risks associated with taking the drug, the drug’s manufacturer(s) may be held liable.
When it comes to filing a civil action to recover damages for harm caused by Xarelto’s dangerous side effects, knowing where to begin can be overwhelming. Our attorneys are committed to working with victims just like you. You do not have to tackle a large pharmaceutical company on your own; we are here to help. To learn more,
call our experienced Texas defective pharmaceutical attorneys at 888-909-9452.
http://xareltolawyerhelp.com/side-effects/

Return to headline | Return to top

Full Text of Articles Below

Add recipients

Suggested